Elevated plasma arginine vasopressin levels in veterans with posttraumatic stress disorder

被引:56
作者
de Kloet, C. S. [1 ,2 ,3 ]
Vermetten, E. [1 ,2 ]
Geuze, E. [1 ,2 ]
Wiegant, V. M. [3 ]
Westenberg, H. G. M. [1 ,2 ]
机构
[1] Cent Mil Hosp, Dept Mil Psychiat, Utrecht, Netherlands
[2] Univ Med Ctr, Dept Psychiat, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands
[3] Univ Utrecht, Med Ctr, Dept Mil Psychiat,Rudolf Magnus Inst Neurosci, Dept Psychiat,Cent Mil Hosp,Dept Pharmacol & Anat, NL-3584 CX Utrecht, Netherlands
关键词
PTSD; arginine vasopressin; trauma; HPA axis; stress;
D O I
10.1016/j.jpsychires.2006.11.009
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Posttraumatic stress disorder (PTSD) is associated with altered hypothalamic-pituitary-adrenal (HPA) axis functioning. Arginine vasopressin (AVP), in conjunction with corticotrophin releasing hormone, has shown to be an important modulator of the HPA axis. In order to evaluate the effect of trauma and PTSD on central AVP secretion we assessed plasma AVP levels in equally trauma exposed veterans with and without PTSD and a non-traumatized healthy control group. Methods: Assessment of plasma AVP in 29 male veterans with PTSD, 29 traumatized veterans without PTSD, matched for age, gender, year and region of deployment (trauma controls), and 26 age matched healthy controls. Results: Plasma AVP levels were higher in PTSD patients compared to both healthy controls (p = 0.004) and trauma controls (p < 0.001). In PTSD patients without a comorbid MDD a significant correlation was observed between plasma AVP levels and symptoms of avoidance measured with the Clinician Administered PTSD Scale (CAPS). Conclusion: Elevated plasma AVP levels are specifically related to PTSD and not to exposure to traumatic stress during deployment. Our results indicate that AVP may play a role as an anxiogenic factor, but they do not support a role for AVP in the altered response to dexamethasone in PTSD. (C) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:192 / 198
页数:7
相关论文
共 51 条
[31]   Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders [J].
Griebel, G ;
Simiand, J ;
Gal, CSL ;
Wagnon, J ;
Pascal, M ;
Scatton, B ;
Maffrand, JP ;
Soubrié, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (09) :6370-6375
[32]   Self-rating Inventory for Posttraumatic Stress Disorder: Review of the psychometric properties of a new brief Dutch screening instrument [J].
Hovens, JE ;
Bramsen, I ;
van der Ploeg, HM .
PERCEPTUAL AND MOTOR SKILLS, 2002, 94 (03) :996-1008
[33]  
KECK ME, 2006, AMINO ACIDS
[34]  
Landgraf R, 1998, PROG BRAIN RES, V119, P201
[35]  
Landgraf Rainer, 2006, CNS & Neurological Disorders-Drug Targets, V5, P167, DOI 10.2174/187152706776359664
[36]   Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjects [J].
Merali, Z ;
Kent, P ;
Du, LS ;
Hrdina, P ;
Palkovits, M ;
Faludi, G ;
Poulter, MO ;
Bédard, T ;
Anisman, H .
BIOLOGICAL PSYCHIATRY, 2006, 59 (07) :594-602
[37]  
Meyerhoff J L, 1990, Adv Exp Med Biol, V274, P91
[38]   Posttraumatic stress disorder: A state-of-the-science review [J].
Nemeroff, CB ;
Bremner, JD ;
Foa, EB ;
Mayberg, HS ;
North, CS ;
Stein, MB .
JOURNAL OF PSYCHIATRIC RESEARCH, 2006, 40 (01) :1-21
[39]   NICOTINE AND THE CENTRAL-NERVOUS-SYSTEM - BIOBEHAVIORAL EFFECTS OF CIGARETTE-SMOKING [J].
POMERLEAU, OF .
AMERICAN JOURNAL OF MEDICINE, 1992, 93 :S2-S7
[40]  
Purba JS, 1996, ARCH GEN PSYCHIAT, V53, P137